

1.

Morak M, Steinke-Lange V, Massdorf T, et al. Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics. *Familial Cancer*. 2020;19(2):161-167. doi:[10.1007/s10689-020-00159-4](https://doi.org/10.1007/s10689-020-00159-4)

2.

Laner A, Benet-Pages A, Neitzel B, Holinski-Feder E. Analysis of 3297 individuals suggests that the pathogenic germline 5'-UTR variant BRCA1 c.-107A > T is not common in south-east Germany. *Familial Cancer*. March 2020. doi:[10.1007/s10689-020-00175-4](https://doi.org/10.1007/s10689-020-00175-4)

3.

Engel C, Ahadova A, Seppälä TT, et al. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. *Gastroenterology*. 2020;158(5):1326-1333. doi:[10.1053/j.gastro.2019.12.032](https://doi.org/10.1053/j.gastro.2019.12.032)

4.

Diebold I, Schön U, Scharf F, et al. Critical assessment of secondary findings in genes linked to primary arrhythmia syndromes. *Human Mutation*. February 2020;humu.23996. doi:[10.1002/humu.23996](https://doi.org/10.1002/humu.23996)

5.

Steinke-Lange V, Holinski-Feder E. Genetic Screening and Personalized Prevention in Colorectal Cancer. *Visc Med*. 2019;35(4):226-230. doi:[10.1159/000501941](https://doi.org/10.1159/000501941)

6.

Steinke-Lange und Holinski-Feder - 2019 - Genetic Screening and Personalized Prevention in C.pdf.

7.

Seppala TT, Ahadova A, Dominguez-Valentin M, et al. Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. *Hered Cancer Clin Pract*. 2019;17:8. doi:[10.1186/s13053-019-0106-8](https://doi.org/10.1186/s13053-019-0106-8)

8.

Morak M, Schaefer K, Steinke-Lange V, et al. Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes. *Eur J Hum Genet*. July 2019. doi:[10.1038/s41431-019-0472-8](https://doi.org/10.1038/s41431-019-0472-8)

9.

Hüneburg R, Aretz S, Büttner R, et al. Empfehlungen zur Früherkennung, Risikoreduktion, Überwachung und Therapie bei Patienten mit Lynch-Syndrom. *Z Gastroenterol*. 2019;57(11):1309-1320. doi:[10.1055/a-1008-9827](https://doi.org/10.1055/a-1008-9827)

10.

Gross M, Holinski-Feder E. [Colorectal cancer prevention and early detection: what is the best strategy?]. *MMW Fortschr Med*. 2019;161(7):43-48. doi:[10.1007/s15006-019-0407-x](https://doi.org/10.1007/s15006-019-0407-x)

11.

Dominguez-Valentin M, Seppälä TT, Sampson JR, et al. Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. *Hered Cancer Clin Pract.* 2019;17(1):28. doi:[10.1186/s13053-019-0127-3](https://doi.org/10.1186/s13053-019-0127-3)

12.

Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med.* July 2019. doi:[10.1038/s41436-019-0596-9](https://doi.org/10.1038/s41436-019-0596-9)

13.

Dominguez-Valentin M, Nakken S, Tubeuf H, et al. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. *Sci Rep.* 2019;9(1):18555. doi:[10.1038/s41598-019-54517-z](https://doi.org/10.1038/s41598-019-54517-z)

14.

Diebold I, Schon U, Horvath R, et al. HADHA and HADHB gene associated phenotypes - Identification of rare variants in a patient cohort by Next Generation Sequencing. *Mol Cell Probes.* 2019;44:14-20. doi:[10.1016/j.mcp.2019.01.003](https://doi.org/10.1016/j.mcp.2019.01.003)

15.

Arnold AM, Morak M, Benet-Pagès A, Laner A, Frishman D, Holinski-Feder E. Targeted deep-intronic sequencing in a cohort of unexplained cases of suspected Lynch syndrome. *Eur J Hum Genet.* December 2019. doi:[10.1038/s41431-019-0536-9](https://doi.org/10.1038/s41431-019-0536-9)

16.

Weren RDA, van der Post RS, Vogelaar IP, et al. Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. *J Med Genet.* 2018;55(10):669-674. doi:[10.1136/jmedgenet-2017-104962](https://doi.org/10.1136/jmedgenet-2017-104962)

17.

von Salome J, Liu T, Keihas M, et al. Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation. *Fam Cancer.* 2018;17(4):531-537. doi:[10.1007/s10689-017-0067-x](https://doi.org/10.1007/s10689-017-0067-x)

18.

Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation. *J Med Genet.* 2018;55(4):240-248. doi:[10.1136/jmedgenet-2017-104744](https://doi.org/10.1136/jmedgenet-2017-104744)

19.

Moller P, Seppala TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut.* 2018;67(7):1306-1316. doi:[10.1136/gutjnl-2017-314057](https://doi.org/10.1136/gutjnl-2017-314057)

20.

Holinski-Feder E, Steinke-Lange V. Das Li-Fraumeni-Syndrom. *TZM News.* 2018;20(2/2018):13-14.

21.

Hallermayr A, Graf J, Koehler U, et al. Extending the critical regions for mutations in the non-coding gene RNU4ATAC in another patient with Roifman Syndrome. *Clin Case Rep.* 2018;6(11):2224-2228. doi:[10.1002/ccr3.1830](https://doi.org/10.1002/ccr3.1830)

22.

Engel C, Vasen HF, Seppala T, et al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. *Gastroenterology.* 2018;155(5):1400-1409.e2. doi:[10.1053/j.gastro.2018.07.030](https://doi.org/10.1053/j.gastro.2018.07.030)

23.

Dominguez-Valentin M, Nakken S, Tubeuf H, et al. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families. *Fam Cancer.* 2018;17(1):141-153. doi:[10.1007/s10689-017-0011-0](https://doi.org/10.1007/s10689-017-0011-0)

24.

Dominguez-Valentin M, Nakken S, Tubeuf H, et al. Identification of genetic variants for clinical management of familial colorectal tumors. *BMC Med Genet.* 2018;19(1):26. doi:[10.1186/s12881-018-0533-9](https://doi.org/10.1186/s12881-018-0533-9)

25.

Dominguez-Valentin M, Evans DGR, Nakken S, et al. Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. *Hered Cancer Clin Pract.* 2018;16:4. doi:[10.1186/s13053-018-0086-0](https://doi.org/10.1186/s13053-018-0086-0)

26.

Braunisch MC, Gallwitz H, Abicht A, et al. Extension of the phenotype of biallelic loss-of-function mutations in SLC25A46 to the severe form of pontocerebellar hypoplasia type I. *Clin Genet.* 2018;93(2):255-265. doi:[10.1111/cge.13084](https://doi.org/10.1111/cge.13084)

27.

Abicht A, Scharf F, Kleinle S, et al. Mitochondrial and nuclear disease panel (Mito-aND-Panel): Combined sequencing of mitochondrial and nuclear DNA by a cost-effective and sensitive NGS-based method. *Mol Genet Genomic Med.* 2018;6(6):1188-1198. doi:[10.1002/mgg3.500](https://doi.org/10.1002/mgg3.500)

28.

Vogelaar IP, van der Post RS, van Krieken JHJ, et al. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. *Eur J Hum Genet.* 2017;25(11):1246-1252. doi:[10.1038/ejhg.2017.138](https://doi.org/10.1038/ejhg.2017.138)

29.

Vargas-Parra GM, Gonzalez-Acosta M, Thompson BA, et al. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis. *Int J Cancer.* 2017;141(7):1365-1380. doi:[10.1002/ijc.30820](https://doi.org/10.1002/ijc.30820)

30.

Seppala T, Pylvanainen K, Evans DG, et al. Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. *Hered Cancer Clin Pract.* 2017;15:18. doi:[10.1186/s13053-017-0078-5](https://doi.org/10.1186/s13053-017-0078-5)

31.

Schrank B, Schoser B, Klopstock T, et al. Lifetime exercise intolerance with lactic acidosis as key manifestation of novel compound heterozygous ACAD9 mutations causing complex I deficiency. *Neuromuscul Disord.* 2017;27(5):473-476. doi:[10.1016/j.nmd.2017.02.005](https://doi.org/10.1016/j.nmd.2017.02.005)

32.

Morak M, Kasbauer S, Kerscher M, et al. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6. *Fam Cancer.* 2017;16(4):491-500. doi:[10.1007/s10689-017-9975-z](https://doi.org/10.1007/s10689-017-9975-z)

33.

Moller P, Seppala T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut.* 2017;66(9):1657-1664. doi:[10.1136/gutjnl-2016-311403](https://doi.org/10.1136/gutjnl-2016-311403)

34.

Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017;66(3):464-472. doi:[10.1136/gutjnl-2015-309675](https://doi.org/10.1136/gutjnl-2015-309675)

35.

Spier I, Kerick M, Drichel D, et al. Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis. *Fam Cancer.* 2016;15(2):281-288. doi:[10.1007/s10689-016-9870-z](https://doi.org/10.1007/s10689-016-9870-z)

36.

Vogelaar IP, Ligtenberg MJL, van der Post RS, et al. Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. *Fam Cancer.* 2016;15(2):289-296. doi:[10.1007/s10689-015-9859-z](https://doi.org/10.1007/s10689-015-9859-z)

37.

Spier I, Drichel D, Kerick M, et al. Low-level APC mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. *J Med Genet.* 2016;53(3):172-179. doi:[10.1136/jmedgenet-2015-103468](https://doi.org/10.1136/jmedgenet-2015-103468)

38.

Rump A, Benet-Pages A, Schubert S, et al. Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. *PLoS Genet.* 2016;12(8):e1006248. doi:[10.1371/journal.pgen.1006248](https://doi.org/10.1371/journal.pgen.1006248)

39.

Lane M, Boczonadi V, Bachtari S, et al. Mitochondrial dysfunction in liver failure requiring transplantation. *J Inherit Metab Dis*. 2016;39(3):427-436. doi:[10.1007/s10545-016-9927-z](https://doi.org/10.1007/s10545-016-9927-z)

41.

Haack TB, Ignatius E, Calvo-Garrido J, et al. Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy. *Am J Hum Genet*. 2016;99(3):735-743. doi:[10.1016/j.ajhg.2016.06.026](https://doi.org/10.1016/j.ajhg.2016.06.026)

41.

Adam R, Spier I, Zhao B, et al. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. *Am J Hum Genet*. 2016;99(2):337-351. doi:[10.1016/j.ajhg.2016.06.015](https://doi.org/10.1016/j.ajhg.2016.06.015)

42.

Spier I, Holzapfel S, Altmüller J, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer*. 2015;137(2):320-331. doi:[10.1002/ijc.29396](https://doi.org/10.1002/ijc.29396)

43.

Severin F, Stollenwerk B, Holinski-Feder E, et al. Economic evaluation of genetic screening for Lynch syndrome in Germany. *Genet Med*. 2015;17(10):765-773. doi:[10.1038/gim.2014.190](https://doi.org/10.1038/gim.2014.190)

44.

Pyle A, Nightingale HJ, Griffin H, et al. Respiratory chain deficiency in nonmitochondrial disease. *Neurol Genet*. 2015;1(1):e6. doi:[10.1212/NXG.0000000000000006](https://doi.org/10.1212/NXG.0000000000000006)

45.

Horpaopan S, Spier I, Zink AM, et al. Genome-wide CNV analysis in 221 unrelated patients and targeted high-throughput sequencing reveal novel causative candidate genes for colorectal adenomatous polyposis. *Int J Cancer*. 2015;136(6):E578-589. doi:[10.1002/ijc.29215](https://doi.org/10.1002/ijc.29215)

46.

Yang R, Chen B, Pfützte K, et al. Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3. *Carcinogenesis*. 2014;35(2):315-323. doi:[10.1093/carcin/bgt344](https://doi.org/10.1093/carcin/bgt344)

47.

Thompson BA, Spurdle AB, Plazzer J-P, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet*. 2014;46(2):107-115. doi:[10.1038/ng.2854](https://doi.org/10.1038/ng.2854)

48.

Taylor RW, Pyle A, Griffin H, et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. *JAMA*. 2014;312(1):68-77. doi:[10.1001/jama.2014.7184](https://doi.org/10.1001/jama.2014.7184)

49.

Steinke V, Holzapfel S, Loeffler M, et al. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. *Int J Cancer*. 2014;135(1):69-77. doi:[10.1002/ijc.28650](https://doi.org/10.1002/ijc.28650)

50.

Morak M, Heidenreich B, Keller G, et al. Biallelic MUTYH mutations can mimic Lynch syndrome. *Eur J Hum Genet*. 2014;22(11):1334-1337. doi:[10.1038/ejhg.2014.15](https://doi.org/10.1038/ejhg.2014.15)

51.

Meshher D, Dove-Edwin I, Sasieni P, et al. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. *Int J Cancer*. 2014;134(4):939-947. doi:[10.1002/ijc.28397](https://doi.org/10.1002/ijc.28397)

52.

Wurfel W, Suttner R, Shakeshaft D, et al. Pregnancy and Birth After a Two-Step PGD: Polar Body Diagnosis for Hemophilia A and Array CGH on Trophectoderm Cells for Chromosomal Aberrations. *Geburtshilfe Frauenheilkd*. 2013;73(8):812-814. doi:[10.1055/s-0033-1350705](https://doi.org/10.1055/s-0033-1350705)

53.

Marina AD, Schara U, Pyle A, et al. NDUFS8-related Complex I Deficiency Extends Phenotype from “PEO Plus” to Leigh Syndrome. *JIMD Rep*. 2013;10:17-22. doi:[10.1007/8904_2012_195](https://doi.org/10.1007/8904_2012_195)

54.

Tomsic J, Liyanarachchi S, Hampel H, et al. An American founder mutation in MLH1. *Int J Cancer*. 2012;130(9):2088-2095. doi:[10.1002/ijc.26233](https://doi.org/10.1002/ijc.26233)

55.

Spier I, Horpaopan S, Vogt S, et al. Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat*. 2012;33(7):1045-1050. doi:[10.1002/humu.22082](https://doi.org/10.1002/humu.22082)

56.

Schneider C, Simon T, Hero B, et al. [18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome. *J Clin Oncol*. 2012;30(14):e140-143. doi:[10.1200/JCO.2011.39.7422](https://doi.org/10.1200/JCO.2011.39.7422)

57.

Rahner N, Brockschmidt FF, Steinke V, et al. Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors. *Fam Cancer*. 2012;11(1):19-26. doi:[10.1007/s10689-011-9489-z](https://doi.org/10.1007/s10689-011-9489-z)

58.

Pallauf A, Schirpenbach C, Zwermann O, et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. *Horm Metab Res*. 2012;44(3):215-220. doi:[10.1055/s-0031-1299730](https://doi.org/10.1055/s-0031-1299730)

59.

Neeve VCM, Samuels DC, Bindoff LA, et al. What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr? *Brain*. 2012;135(Pt 12):3614-3626. doi:[10.1093/brain/aws298](https://doi.org/10.1093/brain/aws298)

60.

Horvath R, Holinski-Feder E, Neeve VCM, et al. A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy. *Mov Disord*. 2012;27(6):789-793. doi:[10.1002/mds.24980](https://doi.org/10.1002/mds.24980)

61.

Horvath R, Czermin B, Gulati S, et al. Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. *J Neurol Neurosurg Psychiatry*. 2012;83(2):174-178. doi:[10.1136/jnnp-2011-301258](https://doi.org/10.1136/jnnp-2011-301258)

62.

Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. *J Clin Oncol*. 2012;30(35):4409-4415. doi:[10.1200/JCO.2012.43.2278](https://doi.org/10.1200/JCO.2012.43.2278)

63.

Bulst S, Holinski-Feder E, Payne B, et al. In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. *Mol Genet Metab*. 2012;107(1-2):95-103. doi:[10.1016/j.ymgme.2012.04.022](https://doi.org/10.1016/j.ymgme.2012.04.022)

64.

Velayos-Baeza A, Holinski-Feder E, Neitzel B, et al. Chorea-acanthocytosis genotype in the original critchley kentucky neuroacanthocytosis kindred. *Arch Neurol*. 2011;68(10):1330-1333. doi:[10.1001/archneurol.2011.239](https://doi.org/10.1001/archneurol.2011.239)

65.

Schara U, von Kleist-Retzow J-C, Lainka E, et al. Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations. *J Inherit Metab Dis*. 2011;34(1):197-201. doi:[10.1007/s10545-010-9250-z](https://doi.org/10.1007/s10545-010-9250-z)

66.

Reilich P, Horvath R, Krause S, et al. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. *J Neurol*. 2011;258(11):1987-1997. doi:[10.1007/s00415-011-6055-4](https://doi.org/10.1007/s00415-011-6055-4)

67.

Morak M, Massdorf T, Sykora H, Kerscher M, Holinski-Feder E. First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. *Eur J Cancer*. 2011;47(7):1046-1055. doi:[10.1016/j.ejca.2010.11.016](https://doi.org/10.1016/j.ejca.2010.11.016)

68.

Morak M, Koehler U, Schackert HK, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet*. 2011;48(8):513-519. doi:[10.1136/jmedgenet-2011-100050](https://doi.org/10.1136/jmedgenet-2011-100050)

69.

Mayr JA, Zimmermann FA, Horvath R, et al. Deficiency of the mitochondrial phosphate carrier presenting as myopathy and cardiomyopathy in a family with three affected children. *Neuromuscul Disord.* 2011;21(11):803-808. doi:[10.1016/j.nmd.2011.06.005](https://doi.org/10.1016/j.nmd.2011.06.005)

70.

Kuiper RP, Vissers LELM, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. *Hum Mutat.* 2011;32(4):407-414. doi:[10.1002/humu.21446](https://doi.org/10.1002/humu.21446)

71.

Komm M, Kronawitter-Fesl M, Kremer M, Lutz L, Holinski-Feder E, Kopp R. Primary mucinous adenocarcinoma of the vermiform appendix with high grade microsatellite instability. *J Cancer.* 2011;2:302-306.

72.

Kohonen-Corish MRJ, Macrae F, Genuardi M, et al. Deciphering the colon cancer genes--report of the InSiGHT-Human Variome Project Workshop, UNESCO, Paris 2010. *Hum Mutat.* 2011;32(4):491-494. doi:[10.1002/humu.21450](https://doi.org/10.1002/humu.21450)

73.

Kempers MJE, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol.* 2011;12(1):49-55. doi:[10.1016/S1470-2045\(10\)70265-5](https://doi.org/10.1016/S1470-2045(10)70265-5)

74.

Kemp JP, Smith PM, Pyle A, et al. Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency. *Brain.* 2011;134(Pt 1):183-195. doi:[10.1093/brain/awq320](https://doi.org/10.1093/brain/awq320)

75.

Huhn S, Ingelfinger D, Bermejo JL, et al. Polymorphisms in CTNNB1 in relation to colorectal cancer with evolutionary implications. *Int J Mol Epidemiol Genet.* 2011;2(1):36-50.

76.

Hardt K, Heick SB, Betz B, et al. Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. *Fam Cancer.* 2011;10(2):273-284. doi:[10.1007/s10689-011-9431-4](https://doi.org/10.1007/s10689-011-9431-4)

77.

Carrai M, Steinke V, Vodicka P, et al. Association Between TAS2R38 Gene Polymorphisms and Colorectal Cancer Risk: A Case-Control Study in Two Independent Populations of Caucasian Origin. Song Y, ed. *PLoS ONE.* 2011;6(6):e20464. doi:[10.1371/journal.pone.0020464](https://doi.org/10.1371/journal.pone.0020464)

78.

Walter MC, Czermin B, Muller-Ziermann S, et al. Late-onset ptosis and myopathy in a patient with a heterozygous insertion in POLG2. *J Neurol.* 2010;257(9):1517-1523. doi:[10.1007/s00415-010-5565-9](https://doi.org/10.1007/s00415-010-5565-9)

79.

Seeger J, Schrank B, Pyle A, et al. Clinical and neuropathological findings in patients with TACO1 mutations. *Neuromuscul Disord.* 2010;20(11):720-724. doi:[10.1016/j.nmd.2010.06.017](https://doi.org/10.1016/j.nmd.2010.06.017)

70.

Reuschenbach M, Kloor M, Morak M, et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. *Fam Cancer.* 2010;9(2):173-179. doi:[10.1007/s10689-009-9307-z](https://doi.org/10.1007/s10689-009-9307-z)

81.

Out AA, Tops CMJ, Nielsen M, et al. Leiden Open Variation Database of the MUTYH gene. *Hum Mutat.* 2010;31(11):1205-1215. doi:[10.1002/humu.21343](https://doi.org/10.1002/humu.21343)

82.

Morak M, Laner A, Bacher U, Keiling C, Holinski-Feder E. MUTYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. *Clin Genet.* 2010;78(4):353-363. doi:[10.1111/j.1399-0004.2010.01478.x](https://doi.org/10.1111/j.1399-0004.2010.01478.x)

83.

Lascorz J, Forsti A, Chen B, et al. Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. *Carcinogenesis.* 2010;31(9):1612-1619. doi:[10.1093/carcin/bgq146](https://doi.org/10.1093/carcin/bgq146)

84.

Koehler U, Holinski-Feder E, Ertl-Wagner B, et al. A novel 1p31.3p32.2 deletion involving the NFIA gene detected by array CGH in a patient with macrocephaly and hypoplasia of the corpus callosum. *Eur J Pediatr.* 2010;169(4):463-468. doi:[10.1007/s00431-009-1057-2](https://doi.org/10.1007/s00431-009-1057-2)

85.

Kenngott S, Olze R, Kollmer M, et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? *Eur J Med Res.* 2010;15(5):220-224. doi:[10.1186/2047-783x-15-5-220](https://doi.org/10.1186/2047-783x-15-5-220)

86.

Holinski-Feder E. [The role of genetic predisposition in early detection of cancer]. *MMW Fortschr Med.* 2010;152(4):35-36.

87.

Finsterer J, Stollberger C, Holinski-Feder E. Recovery of systolic dysfunction in duchenne muscular dystrophy due to the point mutation c.4213C>T. *Cardiology.* 2010;117(4):265-267. doi:[10.1159/000323515](https://doi.org/10.1159/000323515)

88.

Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol.* 2010;8(2):174-182. doi:[10.1016/j.cgh.2009.10.003](https://doi.org/10.1016/j.cgh.2009.10.003)

89.

Campa D, Pardini B, Naccarati A, et al. Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study. *BMC Gastroenterol.* 2010;10(1):112. doi:[10.1186/1471-230X-10-112](https://doi.org/10.1186/1471-230X-10-112)

90.

Beckmann BM, Holinski-Feder E, Walter MC, et al. Laminopathy presenting as familial atrial fibrillation. *Int J Cardiol.* 2010;145(2):394-396. doi:[10.1016/j.ijcard.2010.04.024](https://doi.org/10.1016/j.ijcard.2010.04.024)

91.

Mayer V, Schoen U, Holinski-Feder E, Koehler U, Thalhammer S. Single cell analysis of mutations in the APC gene. *Fetal Diagn Ther.* 2009;26(3):148-156. doi:[10.1159/000248721](https://doi.org/10.1159/000248721)

92.

Horvath R, Kemp JP, Tuppen HAL, et al. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. *Brain.* 2009;132(Pt 11):3165-3174. doi:[10.1093/brain/awp221](https://doi.org/10.1093/brain/awp221)

93.

Horvath R, Bender A, Abicht A, et al. Heteroplasmic mutation in the anticodon-stem of mitochondrial tRNA(Val) causing. *J Neurol.* 2009;256(5):810-815. doi:[10.1007/s00415-009-5023-8](https://doi.org/10.1007/s00415-009-5023-8)

94.

Finke C, Horvath R, Holinski-Feder E, Ploner CJ. [Fragile X-associated tremor/ataxia syndrome]. *Nervenarzt.* 2009;80(12):1473-1479. doi:[10.1007/s00115-009-2846-6](https://doi.org/10.1007/s00115-009-2846-6)

95.

Bulst S, Abicht A, Holinski-Feder E, et al. In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. *Hum Mol Genet.* 2009;18(9):1590-1599. doi:[10.1093/hmg/ddp074](https://doi.org/10.1093/hmg/ddp074)

96.

Papaemmanuil E, Carvajal-Carmona L, Sellick GS, et al. Deciphering the genetics of hereditary non-syndromic colorectal cancer. *Eur J Hum Genet.* 2008;16(12):1477-1486. doi:[10.1038/ejhg.2008.129](https://doi.org/10.1038/ejhg.2008.129)

97.

Morak M, Schackert HK, Rahner N, et al. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. *Eur J Hum Genet.* 2008;16(7):804-811. doi:[10.1038/ejhg.2008.25](https://doi.org/10.1038/ejhg.2008.25)

98.

Morak M, Laner A, Scholz M, Madorf T, Holinski-Feder E. Report on de-novo mutation in the MSH2 gene as a rare event in hereditary nonpolyposis colorectal cancer. *Eur J Gastroenterol Hepatol.* 2008;20(11):1101-1105. doi:[10.1097/MEG.0b013e328305e185](https://doi.org/10.1097/MEG.0b013e328305e185)

99.

Horvath R, Reilmann R, Holinski-Feder E, Ringelstein EB, Klopstock T. The role of complex I genes in MELAS: a novel heteroplasmic mutation 3380G>A in ND1 of mtDNA. *Neuromuscul Disord.* 2008;18(7):553-556. doi:[10.1016/j.nmd.2008.05.002](https://doi.org/10.1016/j.nmd.2008.05.002)

100.

Holinski-Feder E, Morak M. [Hereditary nonpolyposis colorectal carcinoma: state of the art]. *Dtsch Med Wochenschr.* 2008;133(33):1690-1695. doi:[10.1055/s-0028-1082788](https://doi.org/10.1055/s-0028-1082788)

101.

Frank B, Burwinkel B, Bermejo JL, et al. Ten recently identified associations between nsSNPs and colorectal cancer could not be replicated in German families. *Cancer Lett.* 2008;271(1):153-157. doi:[10.1016/j.canlet.2008.05.043](https://doi.org/10.1016/j.canlet.2008.05.043)

102.

Brakensiek K, Frye-Boukhriss H, Malzer M, et al. Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. *Clin Genet.* 2008;74(2):171-177. doi:[10.1111/j.1399-0004.2008.01029.x](https://doi.org/10.1111/j.1399-0004.2008.01029.x)

103.

Bettstetter M, Dechant S, Ruummele P, et al. MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. *Lab Invest.* 2008;88(12):1367-1375. doi:[10.1038/labinvest.2008.100](https://doi.org/10.1038/labinvest.2008.100)

104.

Muller A, Zielinski D, Friedrichs N, et al. Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and. *Virchows Arch Int J Pathol.* 2008;453(1):9-16. doi:10.1007/s00428-008-0637-2

105.

Steinke V, Rahner N, Morak M, et al. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. *Eur J Hum Genet EJHG.* 2008;16(5):587-592. doi:10.1038/ejhg.2008.26

106.

Kruger S, Engel C, Bier A, et al. The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. *Cancer Lett.* 2007;252(1):55-64. doi:[10.1016/j.canlet.2006.12.006](https://doi.org/10.1016/j.canlet.2006.12.006)

107.

Koehler U, Grabowski M, Bacher U, Holinski-Feder E. A new interphase fluorescence in situ hybridization approach for genomic rearrangements involving MLH1 and MSH6 in hereditary nonpolyposis colorectal cancer-suspected mutation-negative patients. *Cancer Genet Cytogenet.* 2007;175(1):81-84. doi:[10.1016/j.cancergencyto.2007.01.008](https://doi.org/10.1016/j.cancergencyto.2007.01.008)

108.

Kloor M, Michel S, Buckowitz B, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. *Int J Cancer*. 2007;121(2):454-458. doi:[10.1002/ijc.22691](https://doi.org/10.1002/ijc.22691)

109.

Eckert A, Kloor M, Giersch A, et al. Microsatellite instability in pediatric and adult high-grade gliomas. *Brain Pathol*. 2007;17(2):146-150. doi:[10.1111/j.1750-3639.2007.00049.x](https://doi.org/10.1111/j.1750-3639.2007.00049.x)

110.

Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. *Eur J Cancer*. 2007;43(9):1348-1360. doi:[10.1016/j.ejca.2007.03.021](https://doi.org/10.1016/j.ejca.2007.03.021)

111.

Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. *Clin Cancer Res*. 2007;13(11):3221-3228. doi:[10.1158/1078-0432.CCR-06-3064](https://doi.org/10.1158/1078-0432.CCR-06-3064)

112.

Aretz S, Stienen D, Uhlhaas S, et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. *J Med Genet*. 2007;44(11):702-709. doi:[10.1136/jmg.2007.052506](https://doi.org/10.1136/jmg.2007.052506)

113.

Pistorius S, Gorgens H, Kruger S, et al. N-acetyltransferase (NAT) 2 acetylator status and age of onset in patients with hereditary nonpolyposis colorectal cancer (HNPCC). *Cancer Lett*. 2006;241(1):150-157. doi:[10.1016/j.canlet.2005.10.018](https://doi.org/10.1016/j.canlet.2005.10.018)

114.

Peters N, Kamm C, Asmus F, et al. Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. *Mov Disord*. 2006;21(1):98-102. doi:[10.1002/mds.20673](https://doi.org/10.1002/mds.20673)

115.

Ollila S, Sarantaus L, Kariola R, et al. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. *Gastroenterology*. 2006;131(5):1408-1417. doi:[10.1053/j.gastro.2006.08.044](https://doi.org/10.1053/j.gastro.2006.08.044)

116.

Kruger S, Engel C, Bier A, et al. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. *Cancer Lett*. 2006;236(2):191-197. doi:[10.1016/j.canlet.2005.05.013](https://doi.org/10.1016/j.canlet.2005.05.013)

117.

Horvath R, Abicht A, Holinski-Feder E, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). *J Neurol Neurosurg Psychiatry*. 2006;77(1):74-76. doi:[10.1136/jnnp.2005.067041](https://doi.org/10.1136/jnnp.2005.067041)

118.

Goecke T, Schulmann K, Engel C, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. *J Clin Oncol.* 2006;24(26):4285-4292. doi:[10.1200/JCO.2005.03.7333](https://doi.org/10.1200/JCO.2005.03.7333)

119.

Engel C, Forberg J, Holinski-Feder E, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. *Int J Cancer.* 2006;118(1):115-122. doi:[10.1002/ijc.21313](https://doi.org/10.1002/ijc.21313)

120.

Wieland I, Sabathil J, Ostendorf A, et al. A missense mutation in the coiled-coil motif of the HP1-interacting domain of. *Neurogenetics.* 2005;6(1):45-47. doi:[10.1007/s10048-004-0190-3](https://doi.org/10.1007/s10048-004-0190-3)

121.

Stepp ML, Cason AL, Finnis M, et al. XLMR in MRX families 29, 32, 33 and 38 results from the dup24 mutation in the ARX (Aristaless related homeobox) gene. *BMC Med Genet.* 2005;6:16. doi:[10.1186/1471-2350-6-16](https://doi.org/10.1186/1471-2350-6-16)

122.

Schiemann U, Gunther S, Gross M, et al. Preoperative serum levels of the carcinoembryonic antigen in hereditary non-polyposis colorectal cancer compared to levels in sporadic colorectal cancer. *Cancer Detect Prev.* 2005;29(4):356-360. doi:[10.1016/j.cdp.2005.04.003](https://doi.org/10.1016/j.cdp.2005.04.003)

123.

Schiemann U, Muller-Koch Y, Gross M, et al. Detection of occult high graded microsatellite instabilities in MMR gene mutation negative HNPCC tumors by addition of complementary marker analysis. *Eur J Med Res.* 2005;10(1):23-28.

124.

Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. *Gastroenterology.* 2005;129(2):537-549. doi:[10.1016/j.gastro.2005.06.005](https://doi.org/10.1016/j.gastro.2005.06.005)

125.

Mueller-Koch Y, Vogelsang H, Kopp R, et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. *Gut.* 2005;54(12):1733-1740. doi:[10.1136/gut.2004.060905](https://doi.org/10.1136/gut.2004.060905)

126.

Mangold E, Pagenstecher C, Friedl W, et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. *Int J Cancer.* 2005;116(5):692-702. doi:[10.1002/ijc.20863](https://doi.org/10.1002/ijc.20863)

127.

Kruger S, Silber A-S, Engel C, et al. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. *Lancet Oncol.* 2005;6(8):566-572. doi:[10.1016/S1470-2045\(05\)70253-9](https://doi.org/10.1016/S1470-2045(05)70253-9)

128.

Kruger S, Bier A, Engel C, et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). *J Med Genet.* 2005;42(10):769-773. doi:[10.1136/jmg.2004.028506](https://doi.org/10.1136/jmg.2004.028506)

129.

Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. *Brain.* 2005;128(Pt 8):1855-1860. doi:[10.1093/brain/awh535](https://doi.org/10.1093/brain/awh535)

130.

Grabowski M, Mueller-Koch Y, Grasbon-Frodl E, et al. Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families. *Genet Test.* 2005;9(2):138-146. doi:[10.1089/gte.2005.9.138](https://doi.org/10.1089/gte.2005.9.138)

131.

Schiemann U, Muller-Koch Y, Gross M, et al. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features. *Digestion.* 2004;69(3):166-176. doi:[10.1159/000078223](https://doi.org/10.1159/000078223)

132.

Plaschke J, Kruger S, Dietmaier W, et al. Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. *Hum Mutat.* 2004;23(3):285. doi:[10.1002/humu.9217](https://doi.org/10.1002/humu.9217)

133.

Plaschke J, Engel C, Kruger S, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol.* 2004;22(22):4486-4494. doi:[10.1200/JCO.2004.02.033](https://doi.org/10.1200/JCO.2004.02.033)

134.

Keller G, Vogelsang H, Becker I, et al. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. *J Med Genet.* 2004;41(6):e89. doi:[10.1136/jmg.2003.015594](https://doi.org/10.1136/jmg.2003.015594)

135.

Christophe-Hobertus C, Kooy F, Gecz J, et al. TM4SF10 gene sequencing in XLMR patients identifies common polymorphisms but no disease-associated mutation. *BMC Med Genet.* 2004;5:22. doi:[10.1186/1471-2350-5-22](https://doi.org/10.1186/1471-2350-5-22)

136.

Cederquist K, Emanuelsson M, Goransson I, et al. Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden. *Int J Cancer.* 2004;109(3):370-376. doi:[10.1002/ijc.11718](https://doi.org/10.1002/ijc.11718)

137.

Bauer P, Laccone F, Rolfs A, et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. *J Med Genet.* 2004;41(3):230-232. doi:[10.1136/jmg.2003.015602](https://doi.org/10.1136/jmg.2003.015602)

138.

Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. *Am J Hum Genet.* 2003;72(2):454-464. doi:[10.1086/367713](https://doi.org/10.1086/367713)

139.

Neitzel B, Matern C, Holinski-Feder E. Easy, accurate and reliable screening for SNPs by ion pair/reverse phase HPLC: simultaneous detection of factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T variants. *Clin Lab.* 2003;49(7-8):313-318.

140.

Horsthemke B, Lich C, Buiting K, et al. Problems in detecting mosaic DNA methylation in Angelman syndrome. *Eur J Hum Genet.* 2003;11(12):913-915. doi:[10.1038/sj.ejhg.5201078](https://doi.org/10.1038/sj.ejhg.5201078)

141.

Gasteiger M, Grasbon-Frodl E, Neitzel B, Kooy F, Holinski-Feder E. FMR1 gene deletion/reversion: a pitfall of fragile X carrier testing. *Genet Test.* 2003;7(4):303-308. doi:[10.1089/109065703322783653](https://doi.org/10.1089/109065703322783653)

142.

Golla A, Rost I, Jedele KB, Albert A, Murken J, Holinski-Feder E. MRX42: two linkage intervals, one in the pericentromeric region and one in Xq26, and the impact for carrier risk estimation. *Am J Med Genet.* 2002;107(1):18-25. doi:[10.1002/ajmg.10027](https://doi.org/10.1002/ajmg.10027)

143.

Abidi FE, Holinski-Feder E, Rittinger O, et al. A novel 2 bp deletion in the TM4SF2 gene is associated with MRX58. *J Med Genet.* 2002;39(6):430-433. doi:[10.1136/jmg.39.6.430](https://doi.org/10.1136/jmg.39.6.430)

144.

Oldenburg J, Ivaskevicius V, Rost S, et al. Evaluation of DHPLC in the analysis of hemophilia A. *J Biochem Biophys Methods.* 2001;47(1-2):39-51. doi:[10.1016/s0165-022x\(00\)00150-0](https://doi.org/10.1016/s0165-022x(00)00150-0)

145.

Muller-Koch Y, Kopp R, Lohse P, et al. Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) patients: mutations or polymorphisms? *Eur J Med Res.* 2001;6(11):473-482.

146.

Holinski-Feder E, Muller-Koch Y, Friedl W, et al. DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1 and hMSH2. *J Biochem Biophys Methods.* 2001;47(1-2):21-32. doi:[10.1016/s0165-022x\(00\)00148-2](https://doi.org/10.1016/s0165-022x(00)00148-2)

147.

Pfeifer D, Poulat F, Holinski-Feder E, Kooy F, Scherer G. The SOX8 gene is located within 700 kb of the tip of chromosome 16p and is deleted in a patient with ATR-16 syndrome. *Genomics*. 2000;63(1):108-116. doi:[10.1006/geno.1999.6060](https://doi.org/10.1006/geno.1999.6060)

148.

Holinski-Feder E, Reyniers E, Uhrig S, et al. Familial mental retardation syndrome ATR-16 due to an inherited cryptic subtelomeric translocation, t(3;16)(q29;p13.3). *Am J Hum Genet*. 2000;66(1):16-25. doi:[10.1086/302703](https://doi.org/10.1086/302703)

149.

Laccone F, Engel U, Holinski-Feder E, et al. DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland. *Neurology*. 1999;53(4):801-806. doi:[10.1212/wnl.53.4.801](https://doi.org/10.1212/wnl.53.4.801)

150.

Klopstock T, Chahrokh-Zadeh S, Holinski-Feder E, et al. Markedly different course of Friedreich's ataxia in sib pairs with similar GAA repeat expansions in the frataxin gene. *Acta Neuropathol*. 1999;97(2):139-142. doi:[10.1007/s004010050966](https://doi.org/10.1007/s004010050966)

151.

Holinski-Feder E, Chahrokh-Zadeh S, Rittinger O, et al. Nonsyndromic X-linked mental retardation: mapping of MRX58 to the pericentromeric region. *Am J Med Genet*. 1999;86(2):102-106. doi:[10.1002/\(sici\)1096-8628\(19990910\)86:2<102::aid-ajmg2>3.0.co;2-c](https://doi.org/10.1002/(sici)1096-8628(19990910)86:2<102::aid-ajmg2>3.0.co;2-c)

152.

Jedele KB, Wahl D, Chahrokh-Zadeh S, Wirtz A, Murken J, Holinski-Feder E. Spinal and bulbar muscular atrophy (SBMA): somatic stability of an expanded CAG repeat in fetal tissues. *Clin Genet*. 1998;54(2):148-151. doi:[10.1111/j.1399-0004.1998.tb03718.x](https://doi.org/10.1111/j.1399-0004.1998.tb03718.x)

153.

Holinski-Feder E, Weiss M, Brandau O, et al. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. *Pediatrics*. 1998;101(2):276-284. doi:[10.1542/peds.101.2.276](https://doi.org/10.1542/peds.101.2.276)

154.

Grimm L, Holinski-Feder E, Teodoridis J, et al. Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3'-UTR and alternative splice products. *Hum Mol Genet*. 1998;7(12):1873-1886. doi:[10.1093/hmg/7.12.1873](https://doi.org/10.1093/hmg/7.12.1873)

155.

Vihinen M, Belohradsky BH, Haire RN, et al. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). *Nucleic Acids Res*. 1997;25(1):166-171. doi:[10.1093/nar/25.1.166](https://doi.org/10.1093/nar/25.1.166)

156.

Holinski-Feder E, Jedele KB, Hortnagel K, Albert A, Meindl A, Trenkwalder C. Large intergenerational variation in age of onset in two young patients with Huntington's disease presenting as dyskinesia. *Pediatrics*. 1997;100(5):896-898. doi:[10.1542/peds.100.5.896](https://doi.org/10.1542/peds.100.5.896)

157.

Bocker T, Diermann J, Friedl W, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. *Cancer Res.* 1997;57(21):4739-4743.

158.

Holinski-Feder E, Golla A, Rost I, Seidel H, Rittinger O, Meindl A. Regional localization of two MRX genes to Xq28 (MRX28) and to Xp11.4-Xp22.12 (MRX33). *Am J Med Genet.* 1996;64(1):125-130.doi:[10.1002/\(SICI\)1096-8628\(19960712\)64:1<125::AID-AJMG21>3.0.CO;2-O](https://doi.org/10.1002/(SICI)1096-8628(19960712)64:1<125::AID-AJMG21>3.0.CO;2-O)

159.

Holinski-Feder E, Chahrokh-Zadeh S, Jedele KB, Meindl A, Steinbach P, Wohrle D. FRAXE testing. *Am J Hum Genet.* 1996;59(5):1168-1169.